Tofacitinib cost saving in moderate-to-severe RA in China

  • PDF / 170,614 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 63 Downloads / 216 Views

DOWNLOAD

REPORT

1173-5503/20/0863-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 3 Oct 2020 No. 863

1

Data Loading...

Recommend Documents
Cost Saving

189 18 57MB

Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China

189 21 1MB

Cost-Saving Intervention

160 50 32KB

Cost of Disasters in China

179 109 936KB

Bariatric surgery cost saving in obese patients requiring insulin

169 87 182KB

Dapagliflozin cost-saving alternative to DPP-4 inhibitors in T2DM

179 74 166KB

Rotavirus vaccine effective and cost saving in Hong Kong

138 15 166KB

Increasing influenza vax coverage cost saving in the EU

153 13 124KB

Teledermatology triage system cost saving in US managed-care setting

160 52 167KB

Individualised screening for diabetic retinopathy cost saving

178 26 166KB

Tofacitinib

134 52 167KB

Tofacitinib

142 36 170KB